Generex Biotechnology Corporation (GNBT)

Recent filings

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 18 - Subsequent... - March 20, 2020

Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2 Coronavirus Pandemic - March 19, 2020

Generex Biotechnology: Generex Signs Contract With Epivax To Develop Ii-Key Peptide Vaccines To Address The Coronavirus Pandemic - March 17, 2020

Notification of inability to timely file Form 10-Q or 10-QSB - March 16, 2020

On march - March 13, 2020

Generex Subsidiary NuGenerex Immuno-Oncology (Formerly Antigen Express) Files Form 10 Registration Statement with the Securities and Exchange Commission - March 12, 2020

Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media - March 11, 2020

Generex Biotechnology Subsidiary NuGenerex Immuno-Oncology Sponsors Susan G. Komen More Than Pink Walk - March 10, 2020

Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic - March 4, 2020

Generex Biotechnology Appoints Independent Director S. Gail Eckhardt, MD to the NuGenerex Immuno-Oncology Board of Directors - March 2, 2020

Generex Biotechnology: Generex Signs Contract With Chinese Partners Beijing Zhonghua Investment Fund Management Co., Ltd And Sinotek-Advocates International Industry Development (Shenzhen) Co., Ltd. T - March 2, 2020

Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines - Feb. 27, 2020

Generex Issues Clarification on Stock Dividends - Feb. 26, 2020

Splits - Feb. 25, 2020

Scheduled Ex-Dividend - Feb. 24, 2020

Ex-Dividend - Feb. 24, 2020

General form for registration of securities under the Securities Act of 1933 - Feb. 18, 2020

Creek Mountain Partners, Inc. just provided an update on share ownership of Generex Biotechnology Corporation - Feb. 13, 2020

Generex Biotechnology Announces Investor Conference Dial-In Details Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines and Corporate Update Thursday February 13, 2020 at 11:00 AM EST - Feb. 12, 2020

Generex Biotechnology Announces Corporate Update and Investor Conference Call: Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines - Thursday February 13, 2020 at 11:00 AM EST - Feb. 10, 2020

Generex Declares NEW Dividend RECORD DATE: Monday, February 17, 2020 - Feb. 7, 2020

Generex Biotechnology Subsidiaries NuGenerex Immuno-Oncology and NuGenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines - Feb. 6, 2020

Generex Provides Stock Dividend Updates and Guidance - Feb. 6, 2020

Generex Biotechnology Appoints Independent Director Carol Nacy, PhD to the NuGenerex Immuno-Oncology Board of Directors - Feb. 5, 2020

Generex Biotechnology Subsidiary Olaregen Therapeutix Receives VAC Approval and Ships Excellagen® to the Arizona Indian Health Service - Feb. 4, 2020

Generex Biotechnology Appoints Independent Directors Craig Eagle, MD and Thomas Leonard to the NuGenerex Immuno-Oncology Board of Directors - Jan. 30, 2020

Entry into a Material Definitive - Jan. 28, 2020

Generex Biotechnology Announces Interview with Richard Purcell, Executive Vice President of R&D - Jan. 24, 2020

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Introduction of Excellagen Aesthetics™ - Jan. 17, 2020

Generex Biotechnology Provides Investor Conference Call Details Tuesday January 21, 2020 at 9:30 AM - Jan. 17, 2020

Generex Biotechnology Provides 2019 Year-End Summary & 2020 Plans - Jan. 16, 2020

Generex Biotechnology Announces Investor Conference Call Scheduled for Tuesday January 21, 2020 at 9:30 AM - Jan. 15, 2020

Generex Biotechnology Announces Interview with President & CEO Joe Moscato - Jan. 13, 2020

Generex Biotechnology Announces Update to Shareholder Stock Dividend - Jan. 10, 2020

Generex Biotechnology to be Featured at 2020 Wall Street Conference - Jan. 8, 2020

Departure of Directors or Certain - Jan. 7, 2020

Generex Biotechnology Announces Update to Shareholder Stock Dividend - Jan. 3, 2020

Generex Biotechnology Issues Shareholder Alert - Dec. 18, 2019

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 18 - Subsequent... - Dec. 16, 2019

General form for registration of securities under the Securities Act of 1933 - Dec. 12, 2019

Generex Biotechnology Appoints Independent Director Marvin S. Hausman, MD to the NuGenerex Immuno-Oncology Board of Directors - Dec. 11, 2019

OTCQB Certification - Dec. 11, 2019

Generex Biotechnology Announces New Structure, Pay Date and Ex-Date for the Previously Postponed Shareholder Stock Dividend and Declares a New Share Dividend in NuGenerex Immuno-Oncology - Dec. 10, 2019

Generex Biotechnology Provides Update on Pending Dividend - Dec. 9, 2019

Generex Biotechnology Announces Funding Update - Dec. 5, 2019

Creek Mountain Partners, Inc. just provided an update on share ownership of Generex Biotechnology Corporation - Nov. 29, 2019

Entry into a Material Definitive - Nov. 27, 2019

Reminder: Generex Investor Conference Call Friday, November 29, 2019 - Nov. 27, 2019

Generex Biotechnology Announces Postponement of Pending 1:1 Dividend - Nov. 27, 2019

Generex Biotechnology Issues Shareholder Alert - Nov. 26, 2019

Generex Biotechnology Signs Stock Purchase Agreement to Acquire 51% of ALTuCELL, Inc. - Nov. 25, 2019

Generex Biotechnology Announces Investor Conference Call Scheduled for Friday November 29, 2019 at 9:30 AM - Nov. 13, 2019

Generex Biotechnology Corporation Just Filed Its Annual Report: Net Income (Loss) pe... - Nov. 12, 2019

Generex Biotechnology Provides Guidance: Form 10k Annual Report will be filed Tuesday Morning November 12th 2019 - Nov. 8, 2019

Generex Biotechnology Announces First-in-Human Clinical Trial of the ALTuCELL Cellular Therapy Product Altsulin® (Microencapsulated Sertoli Cells) - Nov. 5, 2019

Submission of matters to a vote of Security - Oct. 29, 2019

Generex Biotechnology: 1 Stock Dividend - Oct. 29, 2019

Generex Biotechnology Announces Extension to the Pay Date for the Previously Declared 1:1 Stock Dividend - Oct. 29, 2019

Generex Biotechnology: 1 Stock Dividend - Oct. 29, 2019

Current report, item 8.01 - Oct. 29, 2019

Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 - Oct. 29, 2019

Reminder: Generex Investor Conference Call Tomorrow October 29, 2019 - Oct. 28, 2019

Generex Announces Results of Annual Stockholders’ Meeting - Oct. 25, 2019

Generex Biotechnology Announces Investor Conference Call Scheduled for Tuesday October 29, 2019 at 9:30 AM - Oct. 25, 2019

Generex Biotechnology Chief Medical & Scientific Officer Dr. Jason Terrell, MD is Awarded the 2019 Shepperd Pathfinder Award from the John Ben Shepperd Public Leadership Institute - Oct. 18, 2019

Generex Biotechnology Announces Merger with Public Vehicle for Public Trading of NuGenerex Immuno-Oncology - Oct. 15, 2019

Reminder: Generex Investor Conference Call Tomorrow October 15, 2019 - Oct. 14, 2019

Generex Biotechnology Subsidiary Olaregen Therapeutix Launches Excellagen Wound Conforming Matrix 3.0 cc Pre-Filled Syringe - Oct. 1, 2019

Generex Biotechnology Announces Investor Conference Call Scheduled for Tuesday October 15, 2019 at 9:30 AM - Oct. 1, 2019

Generex Biotechnology Subsidiary Olaregen Therapeutix Signs National Sales & Distribution Agreement With AvKare Medical to Distribute Excellagen® Throughout the VA Hospital System - Sept. 30, 2019

Generex Biotechnology Announces Plans to Establish the NuGenerex Diabetes Research Center in Collaboration With Arizona Endocrinology Group & Paradise Valley Medical Family Medicine - Sept. 27, 2019

Generex Biotechnology Corporation releases salary data. CEO sees compensation fall -50% - Sept. 24, 2019

Generex Announces That the Process to Retire 20,375,900 GNBT “Pool Shares” is Complete - Sept. 20, 2019

Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (KeytrudaÒ) for the Treatment of Triple Negative Breast Cancer - Sept. 17, 2019

Generex Announces That the Process to Retire 20,375,900 GNBT “Pool Shares” is Complete - Sept. 16, 2019

Generex Biotechnology Announces Webcast and Invites All Shareholders to See and Listen to the Corporate Presentation from the 21st Annual H.C. Wainwright Global Healthcare Investment Conference - Sept. 12, 2019

Generex Biotechnology Corporation director just declared owning 3,568 shares of Generex Biotechnology Corporation - Sept. 11, 2019

Generex Biotechnology Signs Letters of Intent to Establish NuGenerex Health MSO with Arizona Endocrinology Center & Paradise Valley Family Medicine - Sept. 10, 2019

Generex Announces Date for Annual Shareholder Meeting and Pending Retirement of 20,375,900 GNBT “Pool Shares” - Sept. 6, 2019

Generex Announces Webcast - Sept. 5, 2019

Generex Biotechnology Confirms Record Date for 1:1 Dividend - Sept. 3, 2019

Generex Biotechnology Announces Time Slot for CEO Joe Moscato to Present at H.C. Wainwright Healthcare Conference - Aug. 26, 2019

Generex Biotechnology Reiterates 1:1 Stock Dividend for Clarity in the Market and Provides Details on Capital Structure - Aug. 23, 2019

Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50 - Aug. 19, 2019

Generex Biotechnology Announces Plans for NuGenerex Immuno-Oncology Spinout through a Targeted Acquisition of a Public Company and Planned Merger with Kiromic - Aug. 16, 2019

Generex Biotechnology Defines 1:1 Stock Dividend and Provides Details on Capital Structure - Aug. 15, 2019

Generex Biotechnology Announces Update to the Previously Declared 1:1 Stock Dividend - Aug. 12, 2019

Generex News Alert: Generex to Announce Positive Shareholder News on Monday August 12, 2019 at 8 AM Payment Details for the 1:1 GNBT Stock Dividend - Aug. 9, 2019

Generex Biotechnology Announces Interview with President & CEO Joe Moscato - Aug. 8, 2019

Generex Biotechnology Welcomes MediSource Partners to the NuGenerex Family of Companies - Aug. 1, 2019

Generex Biotechnology Introduces Pantheon Medical, the Newest Member of the NuGenerex Family of Companies - July 31, 2019

Generex Biotechnology Provides a Summary of Its Investor Conference Call Held on July 25, 2019 - July 26, 2019

Reminder: Investor Conference Call Today July 25, 2019 Management to Provide Details on Generex Up-list and 1:1 Stock Dividend - July 25, 2019

Generex Biotechnology Announces Satisfaction of Debt Obligation - July 19, 2019

Generex Biotechnology Announces Investor Conference Call Scheduled for July 25, 2019 - July 16, 2019

Entry into a Material Definitive - July 16, 2019

Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors APMA Annual Scientific Meeting - July 15, 2019

Generex Biotechnology Announces Closing on Acquisition of MediSource Partners - July 12, 2019

Generex Biotechnology Announces Acquisition of Pantheon Medical Foot & Ankle - July 11, 2019

Generex Biotechnology Provides Fiscal Year Overview - July 10, 2019

Sorry, no schedule available for this company

No known shareholders

Generex Biotechnology Corporation (GNBT)

140

cctranscripts

March 20, 2020

Generex Biotechnology Corporation Just Filed Its Quarterly Report: Note 18 - Subsequent... http://www.conferencecalltranscripts.org/pink/summary?id=7627133

cctranscripts

March 19, 2020

Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2 Coronavirus Pandemic http://www.otcmarkets.com/stock/GNBT/news?id=256914

cctranscripts

March 17, 2020

Generex Biotechnology: Generex Signs Contract With Epivax To Develop Ii-Key Peptide Vaccines To Address The Coronavirus Pandemic http://www.conferencecalltranscripts.org/pink/summary?id=7605068

cctranscripts

March 16, 2020

Notification of inability to timely file Form 10-Q or 10-QSB http://www.conferencecalltranscripts.org/pink/summary?id=7599443

cctranscripts

March 13, 2020

On march http://www.conferencecalltranscripts.org/pink/summary?id=7589447

cctranscripts

March 12, 2020

Generex Subsidiary NuGenerex Immuno-Oncology (Formerly Antigen Express) Files Form 10 Registration Statement with the Securities and Exchange Commission http://www.otcmarkets.com/stock/GNBT/news?id=256324

cctranscripts

March 11, 2020

Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media http://www.otcmarkets.com/stock/GNBT/news?id=256233

cctranscripts

March 10, 2020

Generex Biotechnology Subsidiary NuGenerex Immuno-Oncology Sponsors Susan G. Komen More Than Pink Walk http://www.otcmarkets.com/stock/GNBT/news?id=256100

cctranscripts

March 4, 2020

Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic http://www.otcmarkets.com/stock/GNBT/news?id=255670

cctranscripts

March 2, 2020

Generex Biotechnology Appoints Independent Director S. Gail Eckhardt, MD to the NuGenerex Immuno-Oncology Board of Directors http://www.otcmarkets.com/stock/GNBT/news?id=255418

cctranscripts

March 2, 2020

Generex Biotechnology: Generex Signs Contract With Chinese Partners Beijing Zhonghua Investment Fund Management Co., Ltd And Sinotek-Advocates International Industry Development (Shenzhen) Co., Ltd. T http://www.conferencecalltranscripts.org/pink/summary?id=7524875

cctranscripts

Feb. 27, 2020

Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines http://www.otcmarkets.com/stock/GNBT/news?id=255102

cctranscripts

Feb. 26, 2020

Generex Issues Clarification on Stock Dividends http://www.otcmarkets.com/stock/GNBT/news?id=254896

cctranscripts

Feb. 25, 2020

Splits http://www.otcmarkets.com/market-activity/corpActions.jsp?index=4&symbol=GNBT&actionDate=1582606800000

cctranscripts

Feb. 24, 2020

Scheduled Ex-Dividend http://www.otcmarkets.com/market-activity/corpActions.jsp?index=10&id=190205

cctranscripts

Feb. 24, 2020

Ex-Dividend http://www.otcmarkets.com/market-activity/corpActions.jsp?index=9&id=110945

cctranscripts

Feb. 18, 2020

Size too big http://www.sec.gov/Archives/edgar/data/1059784/000160706220000047/0001607062-20-000047-index.htm

cctranscripts

Feb. 13, 2020

Creek Mountain Partners, Inc. just provided an update on share ownership of Generex Biotechnology Corporation http://www.conferencecalltranscripts.org/pink/summary?id=7430165

cctranscripts

Feb. 12, 2020

Generex Biotechnology Announces Investor Conference Dial-In Details Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines and Corporate Update Thursday February 13, 2020 at 11:00 AM EST http://www.otcmarkets.com/stock/GNBT/news?id=253670

cctranscripts

Feb. 10, 2020

Generex Biotechnology Announces Corporate Update and Investor Conference Call: Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines - Thursday February 13, 2020 at 11:00 AM EST http://www.otcmarkets.com/stock/GNBT/news?id=253426
 


Feedback